Flumatinib mesylate

• CAT Number: I005359
• CAS Number: 895519-91-2
• Molecular Formula: C30H33F3N8O4S
• Molecular Weight: 658.69
• Purity: ≥95%
• Synonyms: methanesulfonic acid;4-[(4-methylpiperazin-1-yl)methyl]-N-[6-methyl-5-[(4-pyridin-3-ylpyrimidin-2-yl)amino]pyridin-3-yl]-3-(trifluoromethyl)benzamide
• Target: Bcr-Abl
• Solubility: 10 mM in DMSO
• Storage: Store at -20C
• IC50: 1.2 nM (c-Abl); 307.6 nM(PDGFRβ); 2662 nM (c-Kit) [1]

Flumatinib mesylate (Cat No.:I005359) also known as CS-1023;HHGV678 mesylate, Flumatinib mesylate is primarily used for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML), but no study progress has been published.

Reference

[1]. Luo H, et al. HH-GV-678, a novel selective inhibitor of Bcr-Abl, outperforms imatinib and effectively overrides imatinib resistance. Leukemia. 2010 Oct;24(10):1807-9.
[2]. Zhao J, et al. Flumatinib, a selective inhibitor of BCR-ABL/PDGFR/KIT, effectively overcomes drug resistance of certain KIT mutants. Cancer Sci. 2013 Nov 10.
[3]. Gong A, et al. Metabolism of flumatinib, a novel antineoplastic tyrosine kinase inhibitor, in chronic myelogenous leukemia patients. Drug Metab Dispos. 2010 Aug;38(8):1328-40.